The U.S. Food and Drug Administration on Monday notified healthcare providers that it had received reports of five more deaths in patients using liquid-filled intragastric balloon systems to treat obesity, bringing the total death toll to 12 since 2016.
The balloon systems associated with the reports are made by ReShape Lifesciences and Apollo Endosurgery, the FDA said.
Shares of Apollo Endosurgery and ReShape were both down about 10 percent in late-afternoon trade.
